Saliva Liquid Biopsy Solutions

  • Early Cancer Detection
  • Monitoring Treatment Response
  • Analysis of Resistance
  • Detection of Recurrence

*Testing Availability End of 2021

Press Release
The Research

Saliva Liquid Biopsy Solutions

  • Early Cancer Detection
  • Monitoring Treatment Response
  • Analysis of Resistance
  • Detection of Recurrence

*Testing Availability End of 2021

Press Release
The Research
Interested in a Saliva Diagnostic Research Collaboration?
Interested in Research Collaboration?
SDNA Saliva Collection Device Molecular Diagnostic

Saliva Adds Highly-Valuable
Diagnostic Benefits

In spite of advances in diagnostics and therapeutics, cancer remains the second leading cause of death in the United States. Taking cancer head-on, the Spectrum and UCLA liquid biopsy research collaboration team is actively working to change that. Successful cancer treatments depend not only on better therapies but the critical ability to detect cancer at its earliest stage when treatment is radically more successful.

Cancer is a highly individualized disease. Liquid biopsy using saliva can deliver early detection with the crucial disease data needed for informed, personalized treatments. Spectrum’s saliva collection system is engineered and formulated to maintain quality and critical bio-sample consistency. Two highly pivotal elements essential to understanding cancer and successfully optimizing treatments.

Traditional tumor biopsies remain costly and invasive. Often, when analysis is possible, the tumor is already settled or even in a metastatic state. Additionally, tissue biopsy only provides a single snapshot of the molecular aberration in the tumor at that specific time. New saliva-based liquid biopsies using cell-free circulating tumor DNA (ctDNA) offer a holistic insight into the whole tumor landscape.

Easy, convenient, noninvasive, and pain-free at-home sample self-collection offers patients repeat saliva sampling over extended periods of time. This activity enables the continuous monitoring of treatment response or the emergence of drug resistance. Additionally, the benefit of detecting additional disease activity and mutations help prevent relapses during the course of the disease and beyond for lifelong cancer-free confirmation. While saliva tests won’t replace blood tests for all diagnostic applications, this innovative cancer testing solution has proven to be an incredibly valuable life-saving alternative.

*Testing Availability End of 2021

blank

SDNA Saliva Collection Device Molecular Diagnostic

Saliva Adds Highly-Valuable Diagnostic Benefits

In spite of advances in diagnostics and therapeutics, cancer remains the second leading cause of death in the United States. Taking cancer head-on, the Spectrum and UCLA liquid biopsy research collaboration team is actively working to change that. Successful cancer treatments depend not only on better therapies but the critical ability to detect cancer at its earliest stage when treatment is radically more successful.

Cancer is a highly individualized disease. Liquid biopsy using saliva can deliver early detection with the crucial disease data needed for informed, personalized treatments. Spectrum’s saliva collection system is engineered and formulated to maintain quality and critical bio-sample consistency. Two highly pivotal elements essential to understanding cancer and successfully optimizing treatments.

Traditional tumor biopsies remain costly and invasive. Often, when analysis is possible, the tumor is already settled or even in a metastatic state. Additionally, tissue biopsy only provides a single snapshot of the molecular aberration in the tumor at that specific time. New saliva-based liquid biopsies using cell-free circulating tumor DNA (ctDNA) offer a holistic insight into the whole tumor landscape.

Easy, convenient, noninvasive, and pain-free at-home sample self-collection offers patients repeat saliva sampling over extended periods of time. This activity enables the continuous monitoring of treatment response or the emergence of drug resistance. Additionally, the benefit of detecting additional disease activity and mutations help prevent relapses during the course of the disease and beyond for lifelong cancer-free confirmation. While saliva tests won’t replace blood tests for all diagnostic applications, this innovative cancer testing solution has proven to be an incredibly valuable life-saving alternative.

*Testing Availability End of 2021

blank

blank

Chemistry Enables Earliest Cancer Detection

blank

34% of Cancer Biomarkers Identified in Saliva

blank

Test Identifies Cell-Free DNA shed by Tumers

blank

Saliva is an excellent source of high-quality genomic DNA (gDNA)

74% of DNA in saliva comes from white blood cells

Download Datasheet

A Better
Diagnostic Tool

  • DNA found in saliva is equivalent in quantity & purity to DNA in blood

  • Saliva provides inexpensive and at-home testing reducing affordability & accessibility barriers to early diagnosis

  • Spectrum’s Saliva Liquid Biopsy uses PCR testing and a proprietary assay to accurately identify cell-free circulating tumor DNA (ctDNA)

  • Collection system removes the need for any temperature-controlled storage or transport of testing samples

  • First saliva-based PCR protein preservation solution for qualitative and quantitative early cancer detection (patent-pending)

  • DNA solution’s proprietary formulation delivers higher yields of both single-stranded short and double-stranded ultrashort DNA compared to samples using only raw saliva

  • Saliva collection system & preservation chemistry delivers critical sample consistency for optimal testing accuracy

Easy, Early, and
Pain-Free Detection

UCLA Research shows saliva tests using Spectrum’s saliva collection device and preservation chemistry provide cancer detection at its earliest stages well before even imaging scans are able to locate it. Cancer treatment has shown to be the most successful when cancer is detected early giving patients not only time but more clinical and therapeutic options.

In addition, regular, repeat at-home saliva testing allows clinical teams to monitor and optimize treatment plans over time as the disease progression changes or to confirm cancer remission year over year.

Learn More

Screening, Detection, & Monitoring

For over 150 years proteins have provided vital early indicators of disease. Recent research has identified and cataloged 2290 proteins in whole saliva so far (plasma holds 2698 proteins). Out of all known proteins, 1058 proteins have been identified as cancer biomarkers and 34% have already been found in saliva. To date, 40% of proteins found have been identified as biomarkers for diseases including cancer, cardiovascular disease, and stroke.

*Testing Availability End of 2021

Screening, Detection, & Monitoring

For over 150 years proteins have provided vital early indicators of disease. Recent research has identified and cataloged 2290 proteins in whole saliva so far (plasma holds 2698 proteins). Out of all known proteins, 1058 proteins have been identified as cancer biomarkers and 34% have already been found in saliva. To date, 40% of proteins found have been identified as biomarkers for diseases including cancer, cardiovascular disease, and stroke.

*Testing Availability End of 2021

Saliva Diagnostic UCLA
Research Collaboration Success

Early Cancer Detection  |  Monitoring Treatment Response  |  Analysis of Resistance  |  Detection of Recurrence

What have we learned?

Liquid Biopsy Testing using Saliva for Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer (NSCLC) develops when certain cells mutate in a person’s lungs. When this process starts, a patient will generally not experience any signs or symptoms until cancer grows large enough. Similarly, tumors are only detectable through image scans when they have grown large enough to be seen in those suspected areas. Until this point, cancer is able to grow and spread undetected. Lung cancers may originate in the lungs but can spread to other parts of the body. Approximately 230,000 U.S. citizens a year will receive a lung cancer diagnosis with an estimated 135,000 deaths. Lung cancer deaths have become more numerous than the deaths from prostate, breast, brain, and colorectal cancer combined. It has now become the most common cause of cancer deaths in men and the second most common in women.

Doctors classify lung cancer types according to the size and shape of the cancer cells seen under a microscope. Around 13% of lung cancers are small-cell lung cancers (SCLC) and 84% are non-small cell lung cancers (NSCLC).

NSCLC is an umbrella term that includes several subsets, like adenocarcinoma, squamous cell, and large cell carcinoma. Many people receive a diagnosis of NSCLC after it has spread to other parts of their body. Changes in the DNA of the tumor cells can make cancer spread faster.

Genetic mutations are a natural part of life, and many are harmless. However, when the cells in a person’s lungs mutate in certain ways, NSCLC can develop. Some genetic mutations can make cells develop in uncontrolled and unusual ways. These mutations lead to the growth of tumors, some of which can be cancerous.
NSCLC-causing mutations can arise randomly. However, scientists estimate that roughly 90% of lung cancers have links to tobacco use. Other causes include alcohol use, exposure to ionizing radiation, exposure to radon, and exposure to asbestos.

Successful cancer treatments depend not only on better therapies but the critical ability to detect cancer at its earliest stage when treatment is radically more successful. Cancer is a highly individualized disease. Liquid biopsy using saliva can deliver early detection with the crucial disease data needed for informed, personalized, and effective treatments.

Traditional tumor biopsies remain costly and invasive. Often, when analysis is possible, the tumor is already settled or even in a metastatic state. Additionally, tissue biopsy only provides a single snapshot of the molecular aberration in the tumor at that specific time. The UCLA and Spectrum research collaboration introduces a new saliva-based liquid biopsy approach. This process uses the Spectrum saliva collection system and sample preservation technology to identify cell-free circulating tumor DNA (ctDNA). The easy, noninvasive, and pain-free spit-testing option can be collected in clinic or self-collected at home.

The simple integration of a single saliva test into a yearly wellness exam or even included as part of a twice-a-year preventive dental regimen easily provides the repeat saliva sampling schedule to enable the blanket assurance of the earliest possible detection. After diagnosis, repeat testing affords easy, continuous monitoring for treatment response and the emergence of drug resistance without an office visit. also, the benefit of detecting additional disease activity and mutations help prevent relapses during the course of the disease and beyond for lifelong cancer-free confirmation.

#partoftheSolution

What have we learned?

Liquid Biopsy Testing using Saliva for Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer (NSCLC) develops when certain cells mutate in a person’s lungs. When this process starts, a patient will generally not experience any signs or symptoms until cancer grows large enough. Similarly, tumors are only detectable through image scans when they have grown large enough to be seen in those suspected areas. Until this point, cancer is able to grow and spread undetected. Lung cancers may originate in the lungs but can spread to other parts of the body. Approximately 230,000 U.S. citizens a year will receive a lung cancer diagnosis with an estimated 135,000 deaths. Lung cancer deaths have become more numerous than the deaths from prostate, breast, brain, and colorectal cancer combined. It has now become the most common cause of cancer deaths in men and the second most common in women.

Doctors classify lung cancer types according to the size and shape of the cancer cells seen under a microscope. Around 13% of lung cancers are small-cell lung cancers (SCLC) and 84% are non-small cell lung cancers (NSCLC).

NSCLC is an umbrella term that includes several subsets, like adenocarcinoma, squamous cell, and large cell carcinoma. Many people receive a diagnosis of NSCLC after it has spread to other parts of their body. Changes in the DNA of the tumor cells can make cancer spread faster.

Genetic mutations are a natural part of life, and many are harmless. However, when the cells in a person’s lungs mutate in certain ways, NSCLC can develop. Some genetic mutations can make cells develop in uncontrolled and unusual ways. These mutations lead to the growth of tumors, some of which can be cancerous.
NSCLC-causing mutations can arise randomly. However, scientists estimate that roughly 90% of lung cancers have links to tobacco use. Other causes include alcohol use, exposure to ionizing radiation, exposure to radon, and exposure to asbestos.

Successful cancer treatments depend not only on better therapies but the critical ability to detect cancer at its earliest stage when treatment is radically more successful. Cancer is a highly individualized disease. Liquid biopsy using saliva can deliver early detection with the crucial disease data needed for informed, personalized, and effective treatments.

Traditional tumor biopsies remain costly and invasive. Often, when analysis is possible, the tumor is already settled or even in a metastatic state. Additionally, tissue biopsy only provides a single snapshot of the molecular aberration in the tumor at that specific time. The UCLA and Spectrum research collaboration introduces a new saliva-based liquid biopsy approach. This process uses the Spectrum saliva collection system and sample preservation technology to identify cell-free circulating tumor DNA (ctDNA). The easy, noninvasive, and pain-free spit-testing option can be collected in clinic or self-collected at home.

The simple integration of a single saliva test into a yearly wellness exam or even included as part of a twice-a-year preventive dental regimen easily provides the repeat saliva sampling schedule to enable the blanket assurance of the earliest possible detection. After diagnosis, repeat testing affords easy, continuous monitoring for treatment response and the emergence of drug resistance without an office visit. also, the benefit of detecting additional disease activity and mutations help prevent relapses during the course of the disease and beyond for lifelong cancer-free confirmation.

#partoftheSolution
Contact Us

Can we answer any questions?

Let’s connect.

#partofthesolution

Associations, Memberships & Credentials